Q2 EPS Estimate for Bausch Health Cos Increased by Analyst

Bausch Health Cos Inc. (NYSE:BHC) – Stock analysts at Zacks Research raised their Q2 2026 earnings per share estimates for Bausch Health Cos in a report issued on Tuesday, May 19th. Zacks Research analyst Team now expects that the company will post earnings of $0.96 per share for the quarter, up from their prior estimate of $0.94. The consensus estimate for Bausch Health Cos’ current full-year earnings is $4.08 per share. Zacks Research also issued estimates for Bausch Health Cos’ Q3 2026 earnings at $1.04 EPS, Q4 2026 earnings at $1.15 EPS, FY2026 earnings at $3.93 EPS, Q2 2027 earnings at $0.82 EPS, Q4 2027 earnings at $0.95 EPS, FY2027 earnings at $3.63 EPS, Q1 2028 earnings at $0.60 EPS and FY2028 earnings at $3.10 EPS.

Several other research analysts have also recently weighed in on the company. Barclays reduced their price objective on Bausch Health Cos from $8.00 to $7.00 and set an “equal weight” rating for the company in a research report on Wednesday, February 25th. Weiss Ratings cut Bausch Health Cos from a “sell (d)” rating to a “sell (d-)” rating in a research report on Monday, May 4th. Royal Bank Of Canada lowered their target price on Bausch Health Cos from $10.00 to $9.00 and set a “sector perform” rating on the stock in a research note on Monday, April 27th. Raymond James Financial reiterated a “market perform” rating on shares of Bausch Health Cos in a research note on Monday, January 26th. Finally, Wall Street Zen cut Bausch Health Cos from a “strong-buy” rating to a “buy” rating in a research note on Sunday, February 15th. Four research analysts have rated the stock with a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company presently has an average rating of “Reduce” and an average target price of $8.00.

Bausch Health Cos Stock Down 0.5%

BHC stock opened at $5.32 on Wednesday. The company has a debt-to-equity ratio of 54.68, a current ratio of 1.32 and a quick ratio of 0.97. The stock has a market capitalization of $1.99 billion, a P/E ratio of -1.64 and a beta of 0.42. The business has a 50-day moving average of $5.42 and a 200-day moving average of $6.14. Bausch Health Cos has a fifty-two week low of $4.41 and a fifty-two week high of $8.69.

Bausch Health Cos (NYSE:BHC) last posted its earnings results on Wednesday, April 29th. The company reported $0.78 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.81 by ($0.03). Bausch Health Cos had a negative net margin of 11.47% and a negative return on equity of 2,922.77%. The business had revenue of $2.46 billion during the quarter, compared to analyst estimates of $2.37 billion.

Hedge Funds Weigh In On Bausch Health Cos

Institutional investors have recently modified their holdings of the business. Dynamic Technology Lab Private Ltd purchased a new stake in shares of Bausch Health Cos during the first quarter worth $68,000. Jones Financial Companies Lllp grew its stake in shares of Bausch Health Cos by 1,548.9% in the first quarter. Jones Financial Companies Lllp now owns 24,965 shares of the company’s stock worth $162,000 after purchasing an additional 23,451 shares during the last quarter. Goldman Sachs Group Inc. grew its stake in shares of Bausch Health Cos by 97.1% in the first quarter. Goldman Sachs Group Inc. now owns 948,322 shares of the company’s stock worth $6,136,000 after purchasing an additional 467,270 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its holdings in Bausch Health Cos by 3.1% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 324,847 shares of the company’s stock worth $2,102,000 after buying an additional 9,834 shares during the period. Finally, Geode Capital Management LLC lifted its holdings in Bausch Health Cos by 11.2% in the second quarter. Geode Capital Management LLC now owns 840,418 shares of the company’s stock worth $5,597,000 after buying an additional 84,892 shares during the period. 78.65% of the stock is owned by institutional investors.

Key Headlines Impacting Bausch Health Cos

Here are the key news stories impacting Bausch Health Cos this week:

• Positive Sentiment: Zacks Research slightly raised its FY2026 EPS estimate to $3.93 from $3.92, suggesting near-term earnings expectations are still stable. Bausch Health Announces 2026 Annual Meeting of Shareholder Results
• Positive Sentiment: Shareholders elected all 10 director nominees at the 2026 annual meeting, including a new director with pharmaceutical leadership experience, which supports governance continuity. Bausch Health Announces 2026 Annual Meeting of Shareholder Results
• Neutral Sentiment: The company presented at Barclays’ Leveraged Finance Conference, which keeps management visible to investors but does not signal a major new operating update. Bausch Health Companies Inc. (BHC) Presents at Barclays 30th Annual Leveraged Finance Conference 2026 Transcript
• Negative Sentiment: Zacks Research cut EPS estimates for multiple future periods, including FY2027 and FY2028, indicating softer long-term earnings expectations for Bausch Health Cos Inc. (NYSE:BHC).

Bausch Health Cos Company Profile

Bausch Health Cos Inc, formerly known as Valeant Pharmaceuticals International, is a global specialty pharmaceutical company headquartered in Laval, Quebec, Canada. The company operates through two primary segments: Ophthalmology, led by its Bausch + Lomb franchise, and Diversified Brands, which encompasses prescription dermatology, gastrointestinal, neurology and branded pharmaceutical products. Bausch Health develops, manufactures and markets a range of therapeutic and over-the-counter offerings designed to address conditions such as cataracts, dry eye, glaucoma, acne, rosacea, migraine and gastrointestinal disorders.

The Ophthalmology segment under the Bausch + Lomb name provides products for eye health, including prescription drops, contact lens care solutions, intraocular lenses, surgical instruments and diagnostic devices.